Alto Neuroscience, Inc. (NYSE:ANRO) Receives Average Rating of "Moderate Buy" from Brokerages

Key Points

• Alto Neuroscience, Inc. (NYSE:ANRO) received an average rating of "Moderate Buy" from seven analysts, with an average 12-month target price of $8.50.
• In the most recent quarter, Alto Neuroscience reported earnings of ($0.65) per share, missing the consensus estimate of ($0.57) by ($0.08).
• The stock has a current price of $3.96, with a 12-month low of $1.60 and high of $15.04, indicating significant price volatility over the past year.

Shares of Alto Neuroscience, Inc. (NYSE:ANRO - Get Free Report) have been given an average rating of "Moderate Buy" by the seven research firms that are currently covering the stock, MarketBeat Ratings reports. Three equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The average 1 year target price among analysts that have covered the stock in the last year is $8.50.

Separately, HC Wainwright reiterated a "buy" rating and issued a $10.00 price target on shares of Alto Neuroscience in a report on Monday, August 18th.

Alto Neuroscience Stock Down 3.0%

Shares of Alto Neuroscience stock traded down $0.12 on Friday, hitting $3.83. The company had a trading volume of 69,701 shares, compared to its average volume of 74,060. The firm has a market capitalization of $103.74 million, a P/E ratio of -1.60 and a beta of 1.91. Alto Neuroscience has a twelve month low of $1.60 and a twelve month high of $15.04. The company has a debt-to-equity ratio of 0.18, a current ratio of 18.43 and a quick ratio of 18.43. The stock has a 50-day moving average of $3.33 and a 200-day moving average of $2.79.

Alto Neuroscience (NYSE:ANRO - Get Free Report) last released its quarterly earnings results on Wednesday, August 13th. The company reported ($0.65) earnings per share for the quarter, missing the consensus estimate of ($0.57) by ($0.08). Research analysts predict that Alto Neuroscience will post -2.54 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Bank of Montreal Can acquired a new position in shares of Alto Neuroscience in the second quarter valued at approximately $25,000. Ground Swell Capital LLC bought a new stake in shares of Alto Neuroscience in the second quarter worth $27,000. Vanguard Personalized Indexing Management LLC bought a new stake in shares of Alto Neuroscience in the second quarter worth $33,000. Deutsche Bank AG lifted its position in shares of Alto Neuroscience by 31.3% in the fourth quarter. Deutsche Bank AG now owns 15,210 shares of the company's stock worth $64,000 after purchasing an additional 3,629 shares in the last quarter. Finally, Jane Street Group LLC lifted its position in shares of Alto Neuroscience by 72.0% in the fourth quarter. Jane Street Group LLC now owns 18,600 shares of the company's stock worth $79,000 after purchasing an additional 7,783 shares in the last quarter.

Alto Neuroscience Company Profile

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.